Quirós, L. P.; Ugalde, R. Analysis of the Budgetary Impact of Alemtuzumab As Second-Line Therapy, Compared to Natalizumab and Fingolimod, in Patients Previously Treated With Interferon Beta 1b, Diagnosed With Active Relapsing-Remitting Multiple Sclerosis, Treated in the Costa Rican Social Security Fund. Grhta 2019, 6.